Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00470327
Recruitment Status : Recruiting
First Posted : May 7, 2007
Last Update Posted : August 8, 2019
Sponsor:
Collaborator:
Idiopathic Pulmonary Fibrosis Clinical Research Network
Information provided by (Responsible Party):
University of Chicago

Tracking Information
First Submitted Date May 3, 2007
First Posted Date May 7, 2007
Last Update Posted Date August 8, 2019
Actual Study Start Date September 2005
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: October 13, 2016)
Natural history of course of disease in patients with Interstitial lung disease (ILD) [ Time Frame: Yearly ]
We assess mortality roughly yearly but duration is unlimited
Original Primary Outcome Measures Not Provided
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Official Title A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Brief Summary We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
blood
Sampling Method Non-Probability Sample
Study Population Subjects cared for in the ILD (Interstitial Lung Disease)clinic
Condition
  • Interstitial Lung Diseases
  • Idiopathic Pulmonary Fibrosis
  • Sarcoidosis
  • Connective Tissue Disorder
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: May 4, 2007)
4000
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 2025
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Interstitial lung disease

Exclusion Criteria:

  • Does not have Interstitial lung disease
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Spring Maleckar 773-834-4053
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT00470327
Other Study ID Numbers 14163A
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Yes
Plan Description: We will share coded data with no PHI
Responsible Party University of Chicago
Study Sponsor University of Chicago
Collaborators Idiopathic Pulmonary Fibrosis Clinical Research Network
Investigators
Principal Investigator: Mary E Strek, MD University of Chicago
PRS Account University of Chicago
Verification Date August 2019